References
- YOUNG LS, GASCON R, ALAM S, BERMUDER LM: Mono-clonal antibodies for treatment of Grain-negative infec-tions. Rev. Infect. Dis. (1989) 11:S1564–S1571.
- TENG NN, KAPLAN HS, HEBERT JM, MOORE C, DOUGLASII, WUNDERLICH A, BAUDE Al: Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc. Natl. Acad. Sci. USA (1985) 82:1790–1794.
- DINARELLO CA, WOLFF SM: The role of interleukin-1 indisease. New Engl. J. Med. (1993) 328:106–113.
- MCINTYRE KW, STEPAN GJ, KOLINSKY K.D, BENJAMIN WR,PLOCINSKI JM, KAFFKA KL, CAMPEN CA, CHIZZONITE RA, KILIAN PL: Inhibition of interleukin-1 (11–1) binding and bioactivity in vitro and modulation of acute inflamma-tion in vivo by IL-1 receptor antagonist and anti-11-1 receptor monoclonal antibody. J. Exp. Med. (1991) 173:931–939.
- WAKABAYASHI G, GELFAND JA, BURKE JF, THOMPSON RC, DINARELLO CA: A specific receptor antagonist for interleukin-1 prevents Escherichia coii-induced shock in rabbits. FASEB J. (1991) 5:338–343.
- ALEXANDER HR, DOHERTY GM, BURESI I CM, VENZON DJ, NORTON JA: A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotox-emia in mice. J. Exp. Med. (1991) 173:1029–1032.
- FISHER CJ, SLOTMAN GJ, OPAL SM, PRIBBLE JP, EM-MANUEL G, NG D, BLOEDOW DC, CATALANO MA, FOR THE IL-1RA SEPSIS SYNDROME STUDY GROUP: Initial evaluation of human recombinant interleukin-1 recep-tor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicen-ter trial. Crtt. Care Med. (1994) 22:12–21
- KNAUS WA, WAGNER DP, HARRELL FEJ, DRAPER EA: Whatdetermines prognosis in sepsis? Evidence for a compre-hensive individual patient risk assessment approach to the design and analysis of clinical trials. In: Sepsis. Current Perspectives in Path ophysiology and Therapy Rein-hart K, Eyrich K, Sprung C (Eds.), Springer, Berlin (1994):23–37.
- BAGBY GJ, PLESSALA KJ, WILSON LA, THOMPSON JJ,NELSON S: Divergent efficacy of antibody to tumor necrosis factor-a in intravascular and peritonitis mod-els of sepsis. I. Infect. Dis. (1991) 163:83–88.
- ABRAHAM E, WUNDERINK R, SILVERMAN H, PERL TM, NASRAWAY S, LEVY H, BONE R, WENZEL RP, BALK R, ALLRED R et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, control-led, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA (1995) 273:934–941.
- HOFFMAN SL, PUNJABI NH, KUMALA S et at.: ReductionIn mortality in chloramphenicol treated severe typhoid fever by high dose dexasnethasone. New Engl. J. Med. (1984) 310:82–88.
- MARSHALL JC, COOK DJ, CHRISTOU NV, BERNARD GR,SPRUNG CL, SIBBALD WJ: The multiple organ dysfunc-tion (MOD) score: a reliable descriptor of a complex clinical outcome. Crit. Care Med. In press.
- WORKING GROUP ON RECOMMENDATIONS FOR RE-PORTING OF CLINICAL TRIALS IN THE BIOMEDICAL LIT-ERATURE: Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature. Ann. Intern. Med. (1994) 121:894–895
- BONE RC, BALK RA, CERRA FB, DELLINGER RP, FEIN AM,KNAUS WA, SCHEIN RM, S1BBALD WJ: Definition for sepsis and organ failure and guidelines for the use of Innovative therapies in sepsis. Chest (1992) 101: 1644-1655.
- BERNARD GR, DOIG BG, HUDSON G, LEMESHOW S, MARSHALL S, RUSSELL J, SIBBALD J, SPRUNG CL, VINCENT, J-L, WHEELER AP: Quantification of organ failure for clinical trials and clinical practice [Abstract]. Am. J. Respir. Crit. Care Med. (1995) 151:A323.
- KNAUS WA, SUN X, NYSTROM PO, WAGNER DP: Evalu-ation of definitions for sepsis. Chest (1992) 101:1656–1662.
- MARCHANT A, ALEGRE ML, HAKIM A, PIERARD G, MARECAUX G, FRIEDMAN G, DE GROOTE D, KAHN RJ, VINCENT J-L. GOLDMAN M: Clinical and biological sig-nificance of interleukin-10 plasma levels in patients with septic shock. J. Clin. Immunol. (1995) 15:266–273.